Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company initiated a study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease. The study aimed to evaluate the efficacy and safety of Volenrelaxin in treating adults with Chronic Kidney Disease over a 24-week period.
Intervention/Treatment: The study tested Volenrelaxin, a drug administered subcutaneously, in three different doses. A placebo was also used for comparison. Volenrelaxin is intended to improve outcomes for patients with Chronic Kidney Disease.
Study Design: This was an interventional study with a randomized allocation and a parallel intervention model. It employed a double-blind masking approach, meaning both participants and investigators were unaware of the treatment assignments. The primary purpose was treatment-focused.
Study Timeline: The study was first submitted on September 12, 2024, and the last update was submitted on October 1, 2025. However, the study was withdrawn, indicating it did not proceed as planned.
Market Implications: The withdrawal of this study may impact Eli Lilly’s stock performance and investor sentiment, as it suggests a potential setback in developing treatments for Chronic Kidney Disease. This development could also influence the competitive landscape, as investors may look to other companies with active research in this area.
The study has been withdrawn, but further details are available on the ClinicalTrials portal.